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Abstract
Background: Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we
tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck
squamous cell carcinoma (HNSCC) patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy.
Methodology and Findings: 224 patients with HNSCC were treated with either cisplatin-based chemotherapy followed by
surgery and radiotherapy (neoadjuvant group, n=100) or surgery and radiotherapy (non-neoadjuvant group, n=124).
CCND1 expression was assessed by immunohistochemistry. CCND1 levels were analyzed with chemotherapy response,
disease-free survival (DFS) and overall survival (OS). There was no significant difference between the neoadjuvant group
and non-neoadjuvant group in DFS and OS (p=0.929 and p=0.760) when patients treated with the indiscriminate
administration of cisplatin-based chemotherapy. However, in the neoadjuvant group, patients whose tumors showed a low
CCND1 expression more likely respond to chemotherapy (p,0.001) and had a significantly better OS and DFS than those
whose tumors showed a high CCND1 expression (73% vs 8%, p,0.001; 63% vs 6%, p,0.001). Importantly, patients with a
low CCND1 expression in neoadjuvant group received more survival benefits than those in non-neoadjuvant group
(p=0.016), however patients with a high CCND1 expression and treated with neoadjuvant chemotherapy had a significantly
poor OS compared to those treated with surgery and radiotherapy (p=0.032). A multivariate survival analysis also showed
CCND1 expression was an independent predictive factor (p,0.001).
Conclusions: This study suggests that some but not all patients with HNSCC may benefit from neoadjuvant chemotherapy
with cisplatin-based regimen and CCND1 expression may serve as a predictive biomarker in selecting patients undergo less
than two cycles of neoadjuvant chemotherapy.
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Introduction
Worldwide, approximately 635,000 new cases of head and neck
cancer are diagnosed annually and more than 12 percents of these
cases distributed in China. Unfortunately, 3 quarters of Chinese
patients are already in advanced stage when diagnosed, and above
76,000 patients have been dead each year [1]. Although treatment
has greatly improved in the last three decades due to advances in
combined treatment, long-survival in patients with advanced head
and neck squamous cell carcinoma (HNSCC), which accounts for
over 80–90% of malignant tumors, is poor.
Neoadjuvant chemotherapy, which is the use of systemic
chemotherapy before definitive surgery and/or radiotherapy, has
been an attractive approach in the management of HNSCC for
the last 25 years [2]. The benefits of chemotherapy for patients
with advanced HNSCC, as demonstrated by many clinical
studies, include a reduction in the distant metastasis, improved
long-survival, and the preservation of organ function [3,4,5,6].
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gUnfortunately, some studies have failed to demonstrate any
significant improvement in long-survival after neoadjuvant chemo-
therapy [5,7,8]. Recently, Glynne-Jones et al. stated that there was
no benefit in overall survival from cisplatin-based chemotherapy
before radiotherapy and considered that neoadjuvant chemother-
apy might be the sole effective preoperative management strategy in
HNSCC [9,10]. However, some studies have also shown that
patients whose disease responded to neoadjuvant chemotherapy
had a better survival rate in comparison those who did not receive
chemotherapy or who received non-effective chemotherapy
[11,12,13,14,15]. Furthermore, it has been shown that neoadjuvant
chemotherapy can increase the effectiveness of radiotherapy [16].
Thus, neoadjuvant chemotherapy has become an area of intense
study in HNSCC management; however, the original, empiric-
based treatment strategies that have been historically used have
resulted in many patients with chemotherapy-resistant disease, such
that these patients frequently received multiple cycles of toxic
therapy without success before the apparent lack of efficacy was
identified [17].
It is believed that the extreme biological heterogeneity that
defines the chemotherapy-resistant phenotype and prognosis differs
among patients and generally involves many factors. Accumulating
evidence indicates that a high expression of cyclin D1 (CCND1),
which is a key regulator of the G1 phase of the cell cycle, is
associated with chemotherapy resistance and a poor prognosis in
some solid malignant tumors [18,19,20]. Our previous studies have
alsofound that a high expression of CCND1 in HNSCC was closely
associated with cisplatin resistance in vitro and in vivo [21,22]. These
results have led us to hypothesize that CCND1 could be an
important target for chemotherapy response and monitoring
prognosis in patients with locally advanced HNSCC.
In the present study, we developed a predictive assay that is
capable of selecting patients who would receive the largest possible
benefit from cisplatin-based chemotherapy before surgery and
post-operative radiotherapy. As a proof of principle, we investi-
gated the direct link between CCND1 protein expression and the
treatment efficacy in patients with locally advanced HNSCC.
Ultimately, our main goal was to obtain preliminary data on
CCND1 expression, and to evaluate its potential as an
independent molecular predictor for developing personalized
treatment plans for patients with HNSCC.
Methods
Patient samples
All of the patients gave written informed consent in accordance
with institutional guidelines. During January 1999 to March 2005,
all patients with HNSCC, being pathologically diagnosed
squamous cell carcinoma, who were treated at the Department
of Oral and Maxillofacial Surgery, were screened for the study.
Patients inclusion criteria included: (1) a primary and moderately
advanced tumor (clinical stage III/IVa; UICC/AJCC. 7ed., 2010);
(2) complete medical information and follow-up data; (3) a
Karnofsky performance score of at least 60; (4) a WBC count of
greater than 4000/mm
3, a platelet count $100,000/mm
3,a
normal serum calcium level, and a creatine clearance $55 ml/
min; (5) well-compensated or no pulmonary disease as document-
ed by pulmonary function tests (if receiving pingyangmycin); (6) no
previous treatment. The identifier data were terminally coded in
order to maintain patient anonymity.
Treatment protocols
Neoadjuvant chemotherapy. Patients in neoadjuvant group
initially underwent cisplatin-based intravenous chemotherapy. For
the cisplatin-based regimen, patients received cisplatin (platinum-
containing; cell cycle specific agent) at 80 mg/m
2 on day 1,
teniposide (derivative of podophyllotoxin) at 60 mg/m
2 on days
2–4 or vindesine (vinca vlkaloids; mitotic inhibitor) at 1.6 mg/m
2
on day 2, pingyangmycin (antibiotic cancer agent) at 6 mg/m
2 on
day 3–12 of a 21-day cycle. The chemotherapy regimen consisted
of one to two cycles.
Surgery. Patients underwent radical tumor resection within
two to three weeks of completing chemotherapy or within one
week after enrolling in non-neoadjuvant group. The surgical
procedure was selected by surgeons according to tumor site and
local practice. Standardized surgery, including radical tumor
resection, neck lymph node dissection and the reconstruction of
tissue defects (as necessary), was performed.
Radiotherapy. After surgical resection, all patients received
post-operative radiotherapy. Patients underwent radiotherapy
within two to six weeks of completing surgery. The conventional
radiotherapy regimen of five fractions per week from Monday to
Friday with 200 cGy per day was administered. Total dose:
primary tumor area and neck of positive nodes .6000 cGy, neck
of negative nodes .5000 cGy, and positive tumor margins .6500
cGy.
Clinical outcome assessment of neoadjuvant
chemotherapy
The clinical responses to chemotherapy were evaluated no less
than two weeks after patients completed chemotherapy according
to response evaluation criteria in solid tumors (RECIST) [23].
Patients were evaluated for treatment-related toxicity at a
minimum of every seven days according to the National Cancer
Institute Common Toxicity Criteria, version 2.0. The grade of
toxicity per patient was recorded.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using a rabbit
monoclonal antibody against the CCND1 protein [Epitomics,
Inc., United States; Clone-EPR2241 (IHC)-32] and a mouse
monoclonal antibody against human pan-cytokeratin (P-CK)
protein (Santa Cruz Biotechnology, Inc; sc-71838) on 3-mm slides
using 224 paraffin sections via the standard SP method.
The expression level was assessed by manual counting that
was aided by analysis via Image-pro Plus 6.0 (IPP 6.0). The
measurement parameters included the area sum, density mean,
and integrated optical density (IOD). To rule out the nonspecific
stain of CCND1, the P-CK stain was employed in controversial
section (such as suspicious non cancerous cell stain), and then the
function of irregular automated optical inspection (irregular AOI)
was applied by IPP 6.0 software to score. CCND1 expression was
determined by counting 1,000 cells in 10 large graticules visible in
the microscope. All images which were analyzed using IPP 6.0
were verified by two pathologists who were blinded to the results of
the previous assessments and the two groups. When disagreement
existed, a consensus was reached by discussion.
Statistical analysis
The characteristics of patients were expressed as percentages or
means. The baseline data of two groups were compared using non
parametric tests, except that age was compared using independent
sample t test. The association between CCND1 protein expression
and chemotherapy response and prognosis was evaluated via
Fisher’s exact test. For survival analysis, automated IOD scores
were converted into binomial variables of high versus low
expression around the median. The OS was calculated as the
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cause or until the date of the last follow-up, at which point the data
were censored. The DFS was defined as the time from the first day
after treatment to death from any cause or from disease
progression. Survival curves were calculated using the Kaplan-
Meier method. The log-rank test was used to compare the DFS
and OS hazards in the two groups and the survival of CCND1
expression subgroups (high/low expression) between the two
groups. Cox proportional hazard models were utilized for
univariate and multivariate analyses of molecular biomarkers
and other baseline factors with OS. All calculations and analyses
were performed using the SAS 9.2 Statistical Package for Windows
and were two-tailed where appropriate.
Results
Patient characteristics
All 100 eligible patients who underwent cisplatin-based
neoadjuvant chemotherapy + surgery + postoperative radiother-
apy were enrolled as neoadjuvant group in this study, whereas
another 124 successive patients who directly underwent surgery
and postoperative radiotherapy were enrolled as non-neoadjuvant
group. Of the 100 patients who underwent neoadjuvant
chemotherapy, 83 patients underwent a PTP regimen and 17
patients underwent a PVP regimen. The remaining 124 patients
directly underwent surgery and postoperative radiotherapy. In
these patients’ data, the cutoff date of following-up was March 1,
2010 for survivors. The median follow-up for surviving patients
was 107 months [interquartile range (IQR), 75 to 120] for
neoadjuvant group and 102 months [interquartile range (IQR), 78
to 110] for non-neoadjuvant group. The patients’ eligibilities were
well balanced between the two groups (listed in Table 1).
Surgical specimen characteristics
The characteristics of the surgical specimens are detailed in
Table 2. Exactly 116 (52%) of 224 patients had nodal involvement,
with bilateral metastases or lower cervical metastases in 25 of the
116 patients. Tumor margins were histologically analyzed in 210
of 224 patients. Fifteen (7%) of the 210 margins were considered to
be positive. Other histological signs of severity (vascular emboli,
perineural invasion, diffuse infiltration) were present in 124 (55%)
of 224 patients. As shown in Tables 1 and 2, patients were well
matched between the two groups.
Treatment outcome
In neoadjuvant group, 88 (88%) out of 100 patients received
one cycle of chemotherapy, whereas 12 (12%) patients received
two cycles of chemotherapy. Among the patients, 9 (9%) had
complete response (CR), 54 (54%) had partial response (PR), with
the overall response rate of 63%. Twenty-five (25%) of the patients
had stable disease (SD) and 12 (12%) patients had progression
disease (PD). Ten (12 times) out of the 100 patients showed toxicity
grade 3. The most relevant reasons of toxicity in the cisplatin-
based regimens were neutropenia, vomiting and hepatotoxicity.
Radical surgery was performed for all the patients in both
groups. Neck lymph node dissection was performed in 210 (94%)
of the 224 patients, including unilateral regional neck dissection
(n=105), unilateral functional/radical neck dissection (FND/
RND) (n=55), bilateral regional neck dissection (n=7), one side
regional with the other side radical neck dissection (n=30) and
bilateral radical neck dissection (n=13).
After surgery, all the patients underwent post-surgical radio-
therapy. However, the radiation doses could not be determined in
six of the 224 patients due to missing of clinical data. Eighteen
patients voluntarily stopped radiotherapy and additional seven
patients underwent dose modification due to intolerable side
effects.
CCND1 protein expression
CCND1 protein expression was assessed in 224 cases by IHC;
seven cases were excluded from final evaluation due to the lack of
tumor cells in the tissue sections. The CCND1 protein levels in the
tumors of the remaining 217 patients (100 in NG and 117 in SG)
were analyzed. Thirty-eight of the 217 samples were re-evaluated
by P-CK stain and the consensus scores of CCND1 expression
were determined (shown in Figure 1). The median IOD of 217
patients was 31388.46, which was used as the cutoff value to
determine high or low CCND1 expression. As determined by the
chi-square test, there was no association between CCND1
expression and any baseline demographics.
Table 1. Baseline demographics for the 224 patients who
participated in the study.
neoadjuvant non-neoadjuvant
group(n=100) group(n=124)
Variable No % No % P
Age, yrs:
mean ± SD
55.7613.2 58.4613.0 0.125
Gender
Male 74 74.0 89 71.8 0.710
Female 26 26.0 35 28.2
Site
Tongue 38 38.0 48 38.7 0.547
Gingiva 16 16.0 25 20.2
Buccal mucosa 19 19.0 24 19.4
Floor of the
mouth
10 10.0 10 8.1
Oropharynx 10 10.0 11 8.9
Hard palate 7 7.0 4 3.2
Nasal sinuses 0 0.0 2 1.6
Clinical stage
III 37 37.0 47 37.9 0.890
IVa 63 63.0 77 62.1
Pathologic grade
I 73 73.0 96 77.4 0.423
II 23 23.0 25 20.2
III 4 4.0 3 2.4
Smoking history
Smoker 47 47.0 56 45.2 0.863
Nonsmoker 48 48.0 60 48.4
Missing 5 5.0 8 6.4
Alcohol history
Drinker 32 32.0 35 28.3 0.587
Nondrinker 63 63.0 81 65.3
Missing 5 5.0 8 6.4
Abbreviations: SD: standard deviation; neoadjuvant group: cisplatin-based
neoadjuvant chemotherapy followed by surgery and radiotherapy group.
Non-neoadjuvant group: surgery followed by radiotherapy group.
doi:10.1371/journal.pone.0026399.t001
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of unselected patients with HNSCC
During follow-up period, 130 (58%) of the 224 patients had died
(neoadjuvant group: 61 cases and non-neoadjuvant group: 69
cases). Eight patients died as a result of causes unrelated to cancer,
including two in neoadjuvant group and six in non-neoadjuvant
group. The DFS rates in neoadjuvant group and non-neoadjuvant
group were 33% and 40%, and that the OS rates were 39% and
44%, respectively. Compared to conventional treatment (non-
neoadjuvant group), it appears that the addition of chemotherapy
did not improve the long-term survival of the patients in the whole
neoadjuvant group. There was no significant difference by
Kaplan-Meier analysis in DFS (p=0.929, Fig. 2A) and OS
(p=0.760, Fig. 2B) in the two groups.
CCND1 protein expression is significantly correlated with
chemotherapy responses and clinical outcomes
The protein expression of CCND1 exhibited a significant
correlation with chemotherapy response (p,0.001). A low CCND1
protein expression was closely correlated with chemotherapy
response, as 41 (85%) of 48 patients with low CCND1 expressions
showed clinical responses; however, a high CCND1 expression
might forecast chemotherapy failure, as 30 (58%) of 52 patients with
high CCND1 expression showed no clinical response (Table 3).
Table 2. Characteristics of surgical specimens.
neoadjuvant non-neoadjuvant
group group
(n=100) (n=124)
Characteristic No % No % P
Noda histology, N+
No. of patients with positive nodes 52 52.0 64 51.6 0.744
1 18 18.0 21 16.9
$2 except bilateral or lower cervical metastases 19 19.0 33 26.6
$2 with bilateral or lower cervical metastases* 15 15.0 10 8.1
Surgical margin
Missing 7 7.0 7 5.6 0.729
Positive 6 6.0 9 7.3
Negative 87 87.0 108 87.1
Histologic signs of severity (vascular emboli,
perineural invasion, diffuse infiltration)
Missing 3 3.0 5 4.0 0.850
None 42 42.0 50 40.3
Presence 55 55.0 69 55.6
Note: neoadjuvant group: cisplatin-based neoadjuvant chemotherapy followed by surgery and radiotherapy. Non-neoadjuvant group: surgery followed by
radiotherapy. Lower cervical metastases: cervical metastases below the plane of cricoid cartilage inferior margin.
doi:10.1371/journal.pone.0026399.t002
Figure 1. Two typical cases with low and high cyclin D1 expression were tested by cytokeratin stain. Figs. A–D: The low cyclin D1
expression case. A. HE stain (400cyclin D1 expression were tested by cytok D1 stain (400 case. P-CK stain (40000 cases. E–H: The high cyclin D1
expression case. E. HE stain (400cyclin D1 expression were tested by cytok D1 stain (4006); H. P-CK stain (400006).
doi:10.1371/journal.pone.0026399.g001
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neoadjuvant group, we found that the DFS rates were significantly
difference between low and high CCND1 expression subgroups,
which were 63% and 6% (p,0.001, Fig. 2C). A similar result was
observed with the OS rates for patients with low and high CCND1
expressions in neoadjuvant group, which were 73% and 8%
(p,0.001, Fig. 2D). Similarly, in non-neoadjuvant group, the DFS
rates for patients with low and high CCND1 expressions were
51% and 27% (p=0.010, Fig. 2E), and the OS rates with low and
high CCND1 expressions were 52% and 32% (p=0.018, Fig. 2F).
CCND1 expression is an independent risk factor
In the univariate analysis, CCND1 expression (p,0.001),
lymph node status (p,0.001) and histologic signs of severity
(p=0.001) were associated with OS. The interaction between
CCND1 expression and treatment was significantly associated
with OS (p,0.001), suggesting a benefit from chemotherapy in
neoadjuvant group patients with low CCND1 expressions, but a
hazard from chemotherapy with high CCND1 expression when
compared to non-neoadjuvant group. In the multivariate analysis
that included the four factors (CCND1 expression, lymph node
status, histologic signs of severity and the interaction of CCND1
expression6treatment), CCND1 expression (p,0.001), histologic
signs of severity (p=0.019) and lymph node status (p=0.034) were
found to be independent prognosis factors (Table 4).
CCND1 expression as a biomarker to predict who may
benefit from neoadjuvant chemotherapy treatment
As the above analysis showed, CCND1 expression could predict
prognosis in the two groups. When compared the OS in the two
groups with low CCND1 expressions, we found that the patients
from neoadjuvant group would receive more survival benefits than
those from non-neoadjuvant group (p=0.016, Fig. 2G). However,
the patients from neoadjuvant group exhibited a more inferior OS
than those from non-neoadjuvant group in two groups with high
CCND1 protein expressions (p=0.032, Fig. 2H). The results
strongly indicate that the patients with low CCND1 expressions
from neoadjuvant group may receive more of a survival benefit.
Discussion
With regard to HNSCC, standard treatment consists of surgery
followed by radiation therapy in high-risk patients. Neoadjuvant
chemotherapy, including many regimens, has been investigated in
head and neck cancer; however, the results remain inconclusive, if
not negative [6]. A combination of cisplatin and fluorouracil has
been shown to provide high response rates in untreated patients.
Although many publications have reviewed the use of this regimen
in advanced head and neck cancer, marginal tumoricidal activity
at distant sites has been observed [5,7,24]. These results suggest
that the regimens used were not potent enough to exhibit a
therapeutic effect. In a previous clinical trial, we had found that
cisplatin, teniposide or vindesine, and pingyangmycin were several
of the most potent treatments for the patients with HNSCC as
determined by a modified MTT chemosensitivity assay [25].
Thus, this cisplatin-based regimen has been frequently used in
China over the past ten years. In this study, the total response rate
reached 63% considering both T and N sites, while most of the
patients received just one cycle of neoadjuvant chemotherapy.
Although many randomized trials have failed to show a survival
advantage with the use of neoadjuvant chemotherapy, patients
who achieved a clinical response had a more favorable prognosis
[11,26,27,28,29]. In this study, we also found that the indiscrim-
inate administration of neoadjuvant chemotherapy to patients did
not pose a survival benefit but could present a hazard for survival.
The inability to choose the patients who would most benefit
from chemotherapy was the primary cause of treatment failure. In
this study, we found that CCND1 was an effective biomarker to
predict the clinical response and prognosis of patients with
HNSCC. A low CCND1 expression was closely correlated with
chemotherapy response and favorable prognosis, whereas a high
CCND1 expression may predict chemotherapy failure. The results
are consistent with our previous studies showing that high CCND1
expression correlated with cisplatin resistance in oral cancer cells,
in vitro and in vivo [21,22]. Regardless of treatment with neoadjuvant
chemotherapy or not, the patients with low CCND1 expression
exhibited a better long-survival in comparison to those with high
CCND1 expression. The results have shown that CCND1
expression correlated with prognosis is similar to previous reports
[18,19,20,21,22].
It is interesting that patients with low CCND1 expression in the
neoadjuvant group had a significantly better OS than those in the
non-neoadjuvant group (73% vs 52%, p=0.016); however,
patients with high CCND1 expression in the neoadjuvant group
had a worse OS in comparison to those in non-neoadjuvant group
(8% vs 32%, p=0.032). Furthermore, CCND1 expression and
treatment had a significantly strong interaction in terms of
prognosis. These results show that patients with low CCND1
expression have to receive the treatment with cisplatin-based
neoadjuvant chemotherapy and surgery, whereas patients with
high CCND1 expression should receive surgery-based treatment
as early as possible rather than neoadjuvant chemotherapy plus
surgery. According to multivariate analysis, we also found that
CCND1 level was an independent prognosis factor in patients with
HNSCC.
This study was retrospective and was restricted to patient
subsets with samples; thus, all of the results are considered to be
exploratory. In the present study, we chose the IHC method to
evaluate cyclin D1 protein expression in HNSCC primarily
Table 3. CCND1 protein expression and clinical response in
patients with HNSCC who were treated with cisplatin-based
regimens.
Clinical response(n=100)
Response Non-response
No CR PR SD PD
CCND1 expression
Low expression 48 9 32 6 1
High expression 52 0 22 19 11
Total 100 9 54 25 12
P ,0.001
Note: Low expression: IOD score of CCND1 protein expression ,31388.459;
High expression: IOD score of CCND1 protein expression $31388.459.
doi:10.1371/journal.pone.0026399.t003
Figure 2. Kaplan-Meier survival curves for different treatment protocols and biomarker as well as the impact of treatment
procedure according to CCND1 expression.
doi:10.1371/journal.pone.0026399.g002
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method is a semiquantitative technique, IHC analysis is the most
commonly used, simplest, and cheapest protocol in clinical work
[30]. Moreover, it is believed that cyclin D1 protein overexpres-
sion may occur via other mechanisms besides gene amplification,
and the measurement of protein levels would be more informative
than cyclin D1 DNA copies [19,31,32,33]. According to the
obtained results, low cyclin D1 expression at pretreatment
forecasts a better clinical response and an improved DFS and
OS in neoadjuvant chemotherapy patients.
In this paper, a portion of sections were added P-CK stain to
test the accuracy of CCND1 scoring area and to rule out the non-
cancerous cell stain. The results showed that the determined area
and cells which were chosen by researcher and pathologists were
specific and typical. The status of CCND1 expression (low or high
expression) was not changed after these sections reappraised
according to the area and cells of the positive P-CK stain.
Therefore, we have believed that the CCND1 stain alone
combined with irregular AOI function of IPP 6.0 should be a
reliable method of IHC scoring. And we have assumed that the
method of score by IPP software is more objectivity than
microscope count by observer. So the method may be the scoring
trend of dyeing experiment such in future.
In conclusion, our study indicates a key role of CCND1 in
determining chemotherapy response and prognosis. We can select
the patients with HNSCC who have the greatest chance of
benefiting from neoadjuvant chemotherapy by CCND1 expres-
sion. Indeed CCND1 expression may serve as a predictive
biomarker in selecting patients undergo future neoadjuvant
chemotherapeutic clinical trials.
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